Spesolimab connects with Interleukin 1 receptor like 2
Spesolimab, sold under the brand name Spevigo, is a monoclonal antibody medication used for the treatment of generalized pustular psoriasis (GPP). It is an interleukin-36 receptor (IL1RL2/IL1RAP) antibody.It was approved for medical use in the United States in September 2022, and in European Union in December 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.